1. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  2. EGFR

EGFR

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, heparin binding EGF-like growth factor, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras–mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3_ kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C–protein kinase C (PLC-PKC) pathways.

EGFR Isoform Specific Products:

  • EGFR/ErbB1/HER1

  • ErbB2/HER2

  • ErbB3/HER3

  • ErbB4/HER4

EGFR Related Products (95):

Cat. No. Product Name Effect Purity
  • HY-15772
    Osimertinib Inhibitor 99.95%
    Osimertinib (AZD-9291) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
  • HY-50895
    Gefitinib Inhibitor 99.89%
    Gefitinib (ZD1839) is a EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells.
  • HY-10261
    Afatinib Inhibitor 99.99%
    Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.
  • HY-50896
    Erlotinib Inhibitor >98.0%
    Erlotinib is a medication for the treatment of non-small cell lung cancer. It inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-12000
    AG-490 Inhibitor 99.84%
    AG-490 is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
  • HY-109061
    Lazertinib Inhibitor 98.00%
    Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.
  • HY-112299
    TAS6417 Inhibitor 99.55%
    TAS6417 is an EGFR inhibitor and an efficacious drug candidate for patients with NSCLC, with IC50 values ranging from 1.1-8.0 nM.
  • HY-19985
    PF-06459988 Inhibitor 98.72%
    PF-06459988 is an irreversible inhibitor of T790M-Containing EGFR Mutants.
  • HY-50898
    Lapatinib Inhibitor 99.83%
    Lapatinib (GW572016) is a potent EGFR and ErbB2 inhibitor with IC50s of 10.2 and 9.8 nM, respectively.
  • HY-32721
    Neratinib Inhibitor 98.84%
    Neratinib is an orally available, irreversible tyrosine kinase inhibitor with IC50s of 59 nM and 92 nM for HER2 and EGFR, respectively.
  • HY-14596
    Genistein Inhibitor 99.64%
    Genistein, a soy isoflavone, is a multiple tyrosine kinases inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
  • HY-P9907
    Trastuzumab Inhibitor 99.30%
    Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • HY-12008
    Erlotinib Hydrochloride Inhibitor 99.93%
    Erlotinib hydrochloride inhibits purified EGFR kinase with an IC50 of 2 nM.
  • HY-13524
    AG-1478 Inhibitor 99.74%
    AG-1478 is a selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM.
  • HY-13272
    Dacomitinib Inhibitor 99.83%
    Dacomitinib is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.
  • HY-15772A
    Osimertinib mesylate Inhibitor 99.94%
    Osimertinib mesylate (AZD-9291 mesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.
  • HY-P9905
    Cetuximab Inhibitor 99.70%
    Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with antitumor activity.
  • HY-16069
    Tucatinib Inhibitor 98.53%
    Irbinitinib (ARRY-380; ONT-380) is a potent and selective HER2 inhibitor with an IC50 of 8 nM.
  • HY-15730
    Poziotinib Inhibitor 99.92%
    Poziotinib(NOV120101; HM781-36B) is an irreversible Pan-HER inhibitor with IC50s of 3/5/23 nM for HER1/HER2/HER4 respectively.
  • HY-19730
    Olmutinib Inhibitor 99.95%
    Olmutinib (HM61713; BI-1482694) is an irreversible EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.